AU2003222802B2 - The use of hydroxypyridone-derivatives in wound healing - Google Patents
The use of hydroxypyridone-derivatives in wound healing Download PDFInfo
- Publication number
- AU2003222802B2 AU2003222802B2 AU2003222802A AU2003222802A AU2003222802B2 AU 2003222802 B2 AU2003222802 B2 AU 2003222802B2 AU 2003222802 A AU2003222802 A AU 2003222802A AU 2003222802 A AU2003222802 A AU 2003222802A AU 2003222802 B2 AU2003222802 B2 AU 2003222802B2
- Authority
- AU
- Australia
- Prior art keywords
- formula
- compound
- wounds
- radical
- hydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 230000029663 wound healing Effects 0.000 title claims description 14
- 206010052428 Wound Diseases 0.000 claims abstract description 50
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 49
- 150000001875 compounds Chemical class 0.000 claims abstract description 48
- 150000003254 radicals Chemical class 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 14
- -1 octyl radical Chemical class 0.000 claims description 13
- 229910052760 oxygen Inorganic materials 0.000 claims description 13
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 12
- 125000004432 carbon atom Chemical group C* 0.000 claims description 11
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 9
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 8
- 239000006260 foam Substances 0.000 claims description 8
- 229910052717 sulfur Inorganic materials 0.000 claims description 8
- 125000004434 sulfur atom Chemical group 0.000 claims description 8
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 7
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 7
- 241001465754 Metazoa Species 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 7
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 7
- 229910052794 bromium Inorganic materials 0.000 claims description 7
- 239000000460 chlorine Substances 0.000 claims description 7
- 229910052801 chlorine Inorganic materials 0.000 claims description 7
- 239000006071 cream Substances 0.000 claims description 7
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 claims description 7
- 239000000499 gel Substances 0.000 claims description 7
- 239000000243 solution Substances 0.000 claims description 7
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- YUDRVAHLXDBKSR-UHFFFAOYSA-N [CH]1CCCCC1 Chemical compound [CH]1CCCCC1 YUDRVAHLXDBKSR-UHFFFAOYSA-N 0.000 claims description 5
- 125000003118 aryl group Chemical group 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 239000002674 ointment Substances 0.000 claims description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- 208000023329 Gun shot wound Diseases 0.000 claims description 4
- 206010041899 Stab wound Diseases 0.000 claims description 4
- 239000000443 aerosol Substances 0.000 claims description 4
- 235000010290 biphenyl Nutrition 0.000 claims description 4
- 239000004305 biphenyl Substances 0.000 claims description 4
- 238000002316 cosmetic surgery Methods 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- 229930195734 saturated hydrocarbon Natural products 0.000 claims description 4
- 238000001356 surgical procedure Methods 0.000 claims description 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 3
- SNUSZUYTMHKCPM-UHFFFAOYSA-N 1-hydroxypyridin-2-one Chemical class ON1C=CC=CC1=O SNUSZUYTMHKCPM-UHFFFAOYSA-N 0.000 claims description 3
- UDYUIWXQUBNDHC-UHFFFAOYSA-N 6-[[4-(4-chlorophenoxy)phenoxy]methyl]-1-hydroxy-4-methylpyridin-2-one Chemical compound ON1C(=O)C=C(C)C=C1COC(C=C1)=CC=C1OC1=CC=C(Cl)C=C1 UDYUIWXQUBNDHC-UHFFFAOYSA-N 0.000 claims description 3
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 3
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical group OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims description 3
- 235000004866 D-panthenol Nutrition 0.000 claims description 3
- 239000011703 D-panthenol Substances 0.000 claims description 3
- 229920001605 Dextranomer Polymers 0.000 claims description 3
- 241000258180 Echinacea <Echinodermata> Species 0.000 claims description 3
- 241000196324 Embryophyta Species 0.000 claims description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 229960000458 allantoin Drugs 0.000 claims description 3
- 125000004429 atom Chemical group 0.000 claims description 3
- 125000002619 bicyclic group Chemical group 0.000 claims description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims description 3
- SCKYRAXSEDYPSA-UHFFFAOYSA-N ciclopirox Chemical compound ON1C(=O)C=C(C)C=C1C1CCCCC1 SCKYRAXSEDYPSA-UHFFFAOYSA-N 0.000 claims description 3
- 229960003949 dexpanthenol Drugs 0.000 claims description 3
- 229960002864 dextranomer Drugs 0.000 claims description 3
- 235000014134 echinacea Nutrition 0.000 claims description 3
- 239000000284 extract Substances 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 239000011737 fluorine Substances 0.000 claims description 3
- 125000005843 halogen group Chemical group 0.000 claims description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 4
- 239000004615 ingredient Substances 0.000 claims 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 2
- 238000011282 treatment Methods 0.000 abstract description 10
- MBRHNTMUYWQHMR-UHFFFAOYSA-N 2-aminoethanol;6-cyclohexyl-1-hydroxy-4-methylpyridin-2-one Chemical compound NCCO.ON1C(=O)C=C(C)C=C1C1CCCCC1 MBRHNTMUYWQHMR-UHFFFAOYSA-N 0.000 description 46
- 229960004375 ciclopirox olamine Drugs 0.000 description 45
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 16
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 14
- 230000033115 angiogenesis Effects 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 10
- 210000003711 chorioallantoic membrane Anatomy 0.000 description 10
- 230000014509 gene expression Effects 0.000 description 10
- 230000000694 effects Effects 0.000 description 8
- 102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 description 7
- 101000654725 Homo sapiens Histone-lysine N-methyltransferase SETD2 Proteins 0.000 description 7
- 206010021143 Hypoxia Diseases 0.000 description 6
- 235000010443 alginic acid Nutrition 0.000 description 6
- 229920000615 alginic acid Polymers 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 5
- 229960001425 deferoxamine mesylate Drugs 0.000 description 5
- IDDIJAWJANBQLJ-UHFFFAOYSA-N desferrioxamine B mesylate Chemical compound [H+].CS([O-])(=O)=O.CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN IDDIJAWJANBQLJ-UHFFFAOYSA-N 0.000 description 5
- 239000000416 hydrocolloid Substances 0.000 description 5
- 230000007954 hypoxia Effects 0.000 description 5
- 125000004430 oxygen atom Chemical group O* 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 4
- 229920003345 Elvax® Polymers 0.000 description 4
- 108060001084 Luciferase Proteins 0.000 description 4
- 239000005089 Luciferase Substances 0.000 description 4
- 229940072056 alginate Drugs 0.000 description 4
- 230000002491 angiogenic effect Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 235000013601 eggs Nutrition 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 102000003951 Erythropoietin Human genes 0.000 description 3
- 108090000394 Erythropoietin Proteins 0.000 description 3
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 description 3
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 108700008625 Reporter Genes Proteins 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 210000003837 chick embryo Anatomy 0.000 description 3
- 229940105423 erythropoietin Drugs 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 230000036074 healthy skin Effects 0.000 description 3
- 239000000017 hydrogel Substances 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000002884 skin cream Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 2
- KWFQLEGOEWMCCK-UHFFFAOYSA-N 3-ethyl-1h-pyridin-2-one Chemical compound CCC1=CC=CNC1=O KWFQLEGOEWMCCK-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 208000008960 Diabetic foot Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 241000009328 Perro Species 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 208000004210 Pressure Ulcer Diseases 0.000 description 2
- 229920000297 Rayon Polymers 0.000 description 2
- 206010072170 Skin wound Diseases 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 208000000558 Varicose Ulcer Diseases 0.000 description 2
- 238000005299 abrasion Methods 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 235000010410 calcium alginate Nutrition 0.000 description 2
- 239000000648 calcium alginate Substances 0.000 description 2
- 229960002681 calcium alginate Drugs 0.000 description 2
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000002964 rayon Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- WGTYBPLFGIVFAS-UHFFFAOYSA-M tetramethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)C WGTYBPLFGIVFAS-UHFFFAOYSA-M 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 229910052727 yttrium Inorganic materials 0.000 description 2
- QGLWBTPVKHMVHM-KTKRTIGZSA-N (z)-octadec-9-en-1-amine Chemical compound CCCCCCCC\C=C/CCCCCCCCN QGLWBTPVKHMVHM-KTKRTIGZSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- QUAMONVCYKMUNY-UHFFFAOYSA-N 1-hydroxy-4-methyl-6-[[4-(3-phenylprop-2-enoxy)phenoxy]methyl]pyridin-2-one Chemical compound ON1C(=O)C=C(C)C=C1COC(C=C1)=CC=C1OCC=CC1=CC=CC=C1 QUAMONVCYKMUNY-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- KKFDCBRMNNSAAW-UHFFFAOYSA-N 2-(morpholin-4-yl)ethanol Chemical compound OCCN1CCOCC1 KKFDCBRMNNSAAW-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- PYSGFFTXMUWEOT-UHFFFAOYSA-N 3-(dimethylamino)propan-1-ol Chemical compound CN(C)CCCO PYSGFFTXMUWEOT-UHFFFAOYSA-N 0.000 description 1
- MVKDNXIKAWKCCS-UHFFFAOYSA-N 3-methyl-1h-pyridin-2-one Chemical compound CC1=CC=CN=C1O MVKDNXIKAWKCCS-UHFFFAOYSA-N 0.000 description 1
- KSMVBYPXNKCPAJ-UHFFFAOYSA-N 4-Methylcyclohexylamine Chemical compound CC1CCC(N)CC1 KSMVBYPXNKCPAJ-UHFFFAOYSA-N 0.000 description 1
- BRAAURUJHFSPTE-UHFFFAOYSA-N 6-[(4-benzylphenoxy)methyl]-1-hydroxy-4-methylpyridin-2-one Chemical compound ON1C(=O)C=C(C)C=C1COC(C=C1)=CC=C1CC1=CC=CC=C1 BRAAURUJHFSPTE-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical group N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 208000032064 Chronic Limb-Threatening Ischemia Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 208000007163 Dermatomycoses Diseases 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 101100058944 Gallus gallus CALM gene Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000016878 Hypoxia-Inducible Factor 1 Human genes 0.000 description 1
- 108010028501 Hypoxia-Inducible Factor 1 Proteins 0.000 description 1
- 208000005230 Leg Ulcer Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 238000011785 NMRI mouse Methods 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 208000010195 Onychomycosis Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010034576 Peripheral ischaemia Diseases 0.000 description 1
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 108091006296 SLC2A1 Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- SLINHMUFWFWBMU-UHFFFAOYSA-N Triisopropanolamine Chemical compound CC(O)CN(CC(C)O)CC(C)O SLINHMUFWFWBMU-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 239000012790 adhesive layer Substances 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 210000004712 air sac Anatomy 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- NDKBVBUGCNGSJJ-UHFFFAOYSA-M benzyltrimethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)CC1=CC=CC=C1 NDKBVBUGCNGSJJ-UHFFFAOYSA-M 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001767 cationic compounds Chemical class 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 210000001608 connective tissue cell Anatomy 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 238000001804 debridement Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229960000958 deferoxamine Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- NAPSCFZYZVSQHF-UHFFFAOYSA-N dimantine Chemical compound CCCCCCCCCCCCCCCCCCN(C)C NAPSCFZYZVSQHF-UHFFFAOYSA-N 0.000 description 1
- 229950010007 dimantine Drugs 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- LTYMSROWYAPPGB-UHFFFAOYSA-N diphenyl sulfide Chemical class C=1C=CC=CC=1SC1=CC=CC=C1 LTYMSROWYAPPGB-UHFFFAOYSA-N 0.000 description 1
- JRBPAEWTRLWTQC-UHFFFAOYSA-N dodecylamine Chemical compound CCCCCCCCCCCCN JRBPAEWTRLWTQC-UHFFFAOYSA-N 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229910001411 inorganic cation Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical group O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 description 1
- HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 description 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical compound [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 description 1
- CRVGTESFCCXCTH-UHFFFAOYSA-N methyl diethanolamine Chemical compound OCCN(C)CCO CRVGTESFCCXCTH-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- YWFWDNVOPHGWMX-UHFFFAOYSA-N n,n-dimethyldodecan-1-amine Chemical compound CCCCCCCCCCCCN(C)C YWFWDNVOPHGWMX-UHFFFAOYSA-N 0.000 description 1
- HVAAHUDGWQAAOJ-UHFFFAOYSA-N n-benzylethanamine Chemical compound CCNCC1=CC=CC=C1 HVAAHUDGWQAAOJ-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 230000007959 normoxia Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- OIQJEQLSYJSNDS-UHFFFAOYSA-N piroctone Chemical compound CC(C)(C)CC(C)CC1=CC(C)=CC(=O)N1O OIQJEQLSYJSNDS-UHFFFAOYSA-N 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical group OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
- 125000001453 quaternary ammonium group Chemical class 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000003571 reporter gene assay Methods 0.000 description 1
- 229940069575 rompun Drugs 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 231100000075 skin burn Toxicity 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940073455 tetraethylammonium hydroxide Drugs 0.000 description 1
- LRGJRHZIDJQFCL-UHFFFAOYSA-M tetraethylazanium;hydroxide Chemical compound [OH-].CC[N+](CC)(CC)CC LRGJRHZIDJQFCL-UHFFFAOYSA-M 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 230000032895 transmembrane transport Effects 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 231100000747 viability assay Toxicity 0.000 description 1
- 238000003026 viability measurement method Methods 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
- QYEFBJRXKKSABU-UHFFFAOYSA-N xylazine hydrochloride Chemical compound Cl.CC1=CC=CC(C)=C1NC1=NCCCS1 QYEFBJRXKKSABU-UHFFFAOYSA-N 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 150000003754 zirconium Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/721—Dextrans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
Abstract
The present invention relates to the use of compounds of the formula I, <CHEM> in which R<1>; R<2>; R<3> and R<4> have the meanings indicated in the claims, for the treatment of wounds.
Description
WO 03/088966 PCT/EP03/03618 The use of hydroxypyridone-derivatives in wound healing The present invention relates to the use of compounds of the formula I, R2 1 3 R R R4 N 0
OH
in which R 1
R
2
R
3 and R 4 have the meanings indicated below, in wound healing.
Compounds of formula I such as 6-Cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone 2aminoethanol salt, also known as ciclopirox olamine (CPX) are widespread anti-fungal agents used to treat mycoses of the skin and nails since more than 20 years. Apart from its antimycotic activity, CPX is also effective against both gram-positive and gram-negative bacteria (Dittmar, W. et al.(1981) Microbiological laboratory studies with ciclopiroxolamine.
Arzneimittelforschung 31, 1317-1322). CPX is applied as a 1 cream or gel to treat dermatomycoses and as a 8% nail lacquer to treat onychomycoses. CPX is known to inhibit diverse fungal enzymatic activities in microorganisms, including the transmembrane transport of amino acids, potassium and phosphate. However, the general molecular mechanism of the anti-microbial activity of CPX is not exactly known.
In studies addressing the cutaneous effects of a 1% CPX solution applied on rabbit skin over days, occasionally transient reddening of healthy skin and persistent reddening of experimentally wounded skin has been observed (Alpermann, H. and SchUtz, E. (1981) Studies on the pharmacology and toxicology of ciclopiroxolamine. Arzneimittelforschung 31, 1328-1332). Occasionally transient reddening of healthy skin was explained as a side reaction of CPX.
Therapeutic angiogenesis by recombinant angiogenic growth factors or by gene therapy has become an important treatment modality during the past few years (Hockel, M. et al. (1993) Therapeutic angiogenesis. Arch. Surg 128, 423-429). In ongoing human clinical trials, VEGF gene therapy is applied for the treatment of critical limb ischemia and myocardial ischemia. VEGF therapy has also been experimentally investigated in gastric and duodenal ulceration, as well as in dermal ulcers and in cultured skin substitutes.
It has now been found that the compounds of the formula I Have a potent 00 0o angiogenic activity and induce angiogenesis as evidenced by numerous newly Sformed arranged vessels.
Additionally, it has been found that topic application of CPX does not lead Sto gross systemic alterations in VEGF expression, which limits its function to regions of topical application. This is rather safe and highly advantageous compared to gene therapy. Thus, the compounds of the formula I can be used for the treatment of wounds and/or wound healing, because the potent angiogenic activity differs considerably from the known anti-microbial actitivty of the compounds of the formula I. Thus, not only infections are prevented during the treatment of wounds, but also wound healing is improved by e.g. forming of numerous new vessels in and around the wound.
The invention therefore relates to the use of 1-hydroxy-2-pyridones of the formula 1 R2 RbR
(I)
4 R N 0
OH
for the preparation of a pharmaceutical for wound healing, wherein the wounds are abrasions, burns, chaps, crush wounds, cuts, diabetic foot ulcers, gaping wounds, gashs, grafting of organs, gunshot wounds, incisions, scorch wounds, scratches, skin bums, sores, squeeze wounds, stab wounds, transplantation, venous ulcers or wounds due to surgery or plastic surgery, 0 wherein the compound of the formula I is administered topically in the form of
O
c emulsions, ointments, solutions, tinctures, powders, cream or gel preparation or in the form of aerosols or foams, in which R 1
R
2 and R 3 are identical or different and are a hydrogen atom or alkyl 0 5 having 1-4 carbons atoms, and
R
4 is a saturated hydrocarbon radical having 6 to 9 carbon atoms or a radical of Sthe formula II 00 (N Ar-Z--
Y
where X is S or O, Y is a hydrogen atom or up to 2 halogen atoms such as chlorine and/or bromine, Z is a single bond or the divalent radical comprising a) or b) S, or c) -C(R 5
)(R
6 wherein R 5 and R 6 are identical or different and are independently hydrogen atom or (Cl-C 4 )-alkyl; or d) other divalent radicals having 2 to 10 carbon in the form of a chain, which optionally further comprises one or more of the following: i) a carbon-carbon double bond, or ii) O, S, or a moisture thereof, wherein if 2 or more O and/or S atoms or a mixture thereof are present, each O or S atom is separated by at least 2 carbon atoms; and, In any of the foregoing bivalent radicals, the free valences of the carbon atoms of said bivalent radical are saturated by a hydrogen atom, (C1-C4)alkyl, or a mixture thereof; and Ar is an aromatic ring system having up to two rings which can be substituted by up to three radicals from the group consisting of fluorine, chlorine, bromine, methoxy, (C 1
-C
4 )-alkyl, trifluoromethyl and trifluoromethoxy in free or in salt form.
The invention also relates to a method for wound healing in an animal, wherein the wounds are selected from the group consisting of: crush wounds, cuts, gunshot wounds, incisions, squeeze wounds, stab wounds and wounds due to surgery or plastic surgery, which method comprises administering topically to the animal in the form selected from the group consisting of: emulsions, ointments, solutions, tinctures, powders, aerosols, foams, cream and gels, 1-hydroxy-2-pyridones compounds of the formula 1 in which R 1
R
2 and R 3 are identical or different and are a hydrogen atom or alkyl having 1-4 carbons atoms, and
R
4 is a saturated hydrocarbon radical having 6 to 9 carbon atoms or a radical of the formula II Ar-Z x- -CH 2 where X is S or O, Y is a hydrogen atom or up 2 halogen atoms such as chlorine and/or bromine, Z is a single bond or the divalent radical comprising: a) O, or b) S, or c) -C(R 5
)(R
6 wherein R 5 and R 6 are identical or different and are independently hydrogen atom or (C 1
-C
4 )-alkyl; or d) other divalent radicals having 2 to 10 carbon in the form of a chain, which optionally further comprises one or more of the following: i) a carbon-carbon double bond, or ii) O, S, or a moisture thereof, wherein if 2 or more O and/or S atoms or a mixture thereof are present, each O or S atom is separated by at least 2 carbon atoms; and, in any of the foregoing bivalent radicals, the free valences of the carbon atoms of said bivalent radical are saturated by a hydrogen atom, (C 1
-C
4 )-alkyl, or a mixture c thereof; and o 0 Ar is an aromatic ring system having up to two rings which can be (substituted by up to three radicals from the group consisting of fluorine, chlorine, 10 bromine, methoxy, (C 1
-C
4 )-alkyl, trifluoromethyl and trifluoromethoxy in free or in C- salt form The radical denotes a sulphur atom; the radical denotes an oxygen atom. The term "Ar" denotes phenyl or condensed systems such as naphthyl, tetrahydronaphthyl and indenyl, and also isolated systems such as those, which are derived from biphenyl, diphenylalkanes, diphenyl ethers and diphenyl thioethers.
WO 03/088966 WO 03/88966PCT/EP03/03618 4 The term "saturated hydrocarbon radical having 6 to 9 carbon atoms" means that the radical can be straight-chain, branched or cyclic and contains no aliphatic multiple bonds, i.e. no ethylenic or acetylenic bonds. Examples of the R 4 radical are e.g. hexyl, heptyl, octyl, cyclohexyl or cycloheptyl.
The hydrocarbon radical R 4 in the compound of formula I is preferably an -(C-C 8 )-alkyl or cyclohexyl radical, which may also be linked via a methylene or ethylene group to the pyridone ring or can contain an endomethyl group. R4can also be an aromatic radcical which,,however, is preferably bonded to the pyridone radic'al via at least one aliphatic carbon atom.
Important representatives of the class of compound characterised by the formula I are: 6-[4(4ch lorop henoxy)p henoxymethyI-1 -hyd roxy-4-methyl-2-pyrid one, ich Ilorophenoxy) phen oxymethyl-1 -hyd roxy-4-methyl-2-pyrid one, 6-(b iph enylyl1-4-oxymethyl)-1 -hyd roxy-4-m ethyl -2-pyri done, 6-(4-benzyl-phenoxymethyl)-1 -hydroxy-4-methyl-2-pyridone, ich loro-benzyloxy)phenoxymethyl]-1 -hyd roxy-4- methyl -2-pyri done, 6-[4-(4-chlo rop hen oxy)p hen oxyl ethyl]-1 -hydroxy-3,4-di methyl-2-pyridone, ich Ioro benzyl) ph enoxym ethyII-1 hyd roxy-3,4-d im ethyl -2-pyri done, 6-[4-(cin namyloxy)phenoxymethyl]-1 -hydroxy-4-methyl-2-pyridone, 1 -hyd roxy-4-m ethyl [4-(4-triflI u oromethyl phen oxy) ph enoxymethyl-2- pyri done, 1 -hyd roxy-4- methyl -6-cycl oh exyl-2-pyrid one, 1 hyd roxy-4- methylI-6-(2,4,4-t rim ethyl pentyl)-2-p.yrid one, 1 .hydroxy-4-methyl-6-n-hexyl-, -6-iso-hexyl-, -6-n-heptyl- or -6-iso-heptyl-2-pyridone, 1 -hydroxy-4-methyl-6-octyl- or -6-iso-octyl-2-pyridone, in particular 1 -hydroxy-4-methyl-6cyclohexyl-methyl- or -6-cyclohexylethyl-2-pyridone, where the cyclohexyl radical in each case can also carry a methyl radical, 1 -hydroxy-4-methyl-6-(2-bicyclo!I2,2,1]heptyl)-2-pyridone, '1-hyd roxy-3,4-d imethyl-6-benzyI- or -6-dimethylbenzyl-2-pyridone or 1 -hyd roxy-4-methy-6-(B-phenylethyl)-2-pyridone.
WO 03/088966 PCT/EP03/03618 The above-mentioned compounds of the formula I can be employed both in free form and as salts; use in free form is preferred.
If organic bases are used, poorly volatile bases are preferably employed, for example low molecular weight alkanolamines such as ethanolamine, diethanolamine, Nethylethanolamine, N-methyldiethanolamine, triethanolamine, diethylaminoethanol, 2amino-2-methyl-n-propanol, dimethylaminopropanol, 2-amino-2-rmethylpropanediol, triisopropanolamine. Further poorly volatile bases which may be mentioned are, for example, ethylenediamaine, hexamethylenediamine, morpholine, piperidine, piperazine, cyclohexylamine, tributylamine, dodecylamine, N,N-dimethyldodecylamine, stearylamine, oleylamine, benzylamine, dibenzylamine, N-ethylbenzylamine, dimethylstearylamine, N-methylmorpholine, N-methylpiperazine, 4-methylcyclohexylamine, N-hydroxyethylmorpholine. The salts of quaternary ammonium hydroxides such as trimethylbenzylammonium hydroxide, tetramethylammonium hydroxide or tetraethylammonium hydroxide can also be used, and furthermore guanidine and its derivatives, in particular its alkylation products. However, it is also possible to employ, for example, low molecular alkylamines such as methylamine, ethylamine or triethylamine as saltforming agents. Salts with inorganic cations, for example alkali metal salts, in particular sodium, potassium or ammonium salts, alkaline earth metal salts such as in particular the magnesium or calcium salts, and salts with di- to tetravalent cations, for example the zinc, aluminium or zirconium salt, are also suitable for the compounds to be employed according to the invention.
The compounds of the formula I can be prepared, for example, by the process according to US 2 540 218 or US 4 797 409.
The present invention also relates to the use of the compound of the formula I, in which Ar is a bicyclic system, which is derived from biphenyl, diphenylalkane or diphenyl ether.
The present invention also relates to the use of the compound of the formula I, which contains a cyclohexyl radical in the position R 4 WO 03/088966 PCT/EP03/03618 6 The present invention also relates to the use of the compound of the formula I, which contains an octyl radical of the formula -CH 2 -CH(CH3)-CH2-C(CH3)3 in the position R 4 The present invention also relates to the use of the compound of the formula I, wherein 1-hydroxy-4-methyl-6-[4-(4-chlorophenoxy)phenoxymethyl]-2-(1H)pyridone, 1-hydroxy-4methyl-6-cyclohexyl-2-(1H)pyridone or 1-hydroxy-4-methyl-6-(2,4,4-trimethylpentyl)-2- (1H)pyridone is employed.
The present invention also relates to the use of the compounds of the formula I for the production of a pharmaceutical for the treatment of wounds.
Due to the induction of angiogenesis the healing of wounds is improved, because new blood vessels are formed and the supply of the wound with nutrition and oxygen is improved. Thus, also wound healing of uninfected wounds is dramatically increased. The compounds of the formula I do not only prevent infections of the wound by e.g. yeast, bacteria or fungi, but also support wound healing by a better supply of the wound by the induction of newly formed blood vessels. Thus, wound healing of un-infected and infected wounds is improved by the treatment of the compounds of the formula I.
The term "wounds" is understood as meaning e.g. abrasions, burns, chaps, crush wounds, cuts, diabetic foot ulcers, gaping wounds, gashs, grafting of organs, gunshot wounds, incisions, leg ulcers, pressure ulcers, scorch wounds, scratches, skin burns, sores, squeeze wounds, stab wounds, transplantation, venous ulcers or wounds due to surgery or plastic surgery.
The term "wound healing" is understood as meaning regenerative processes for the closing of a wound; especially new forming of capillary vessels and increase of connective tissue and epithelial cells.
The compounds of the formula I and their physiologically tolerable salts can be administered to animals, preferably to mammals, and in particular to humans as pharmaceuticals for the treatment of wounds and/or wound healing. They can be administered on their own, or in mixtures with one another or in the form of pharmaceutical preparations, which permit topical administration. The term "mammals" is understood as meaning e.g. human, horse, cattle, pig, rat, mouse, sheep or dog.
WO 03/088966 PCT/EP03/03618 7 The pharmaceuticals can be administered percutaneously or topically, for example in the form of emulsions, ointments, solutions or tinctures, powders, or in other ways, for example in the form of aerosols or foams. For use according to the invention of the compounds mentioned, liquid, semisolid and solid pharmaceutical preparations are suitable, in particular solutions, cream, ointment, powders and gel preparations, where the latter are preferably used because of their increased release of active compound.
The pharmaceutical preparations according to the invention are prepared in a manner known per se and familiar to one skilled in the art, pharmaceutically acceptable inert inorganic and/or organic carriers being used in addition to the compound(s) of the formula I and/or its (their) physiologically tolerable salts.
The compounds of the formula I can also be incorporated in or on surgical gauze, bandage or dressing.
Suitable dressings are illustrated in more detail by the following examples: Alginate dressings Alginate wound dressings are woven from calcium alginate fibers. Calcium alginate is a marine biopolymer that is derived from seaweed. Alginates are highly absorptive. When the alginates dressing comes into contact with wound exudate, a soft gel is formed, maintaining a moist environment at the wound surface that is conducive to the formation of granulation tissue and epithelialization. Alginate dressings are indicated for heavily exudating wounds, as they have the capacity to absorb as much as 20 times their weight.
Composite dressings They are generally multi-layered, incorporating a nonadherent layer that is in contact with the wound, and various absorbent, wicking, and semi-occlusive layers. The absorptive layer does not incorporate a foam, alginate, hydrocolloid, or hydrogel. A nonwoven adhesive tape backing secures the dressing to the skin. These dressings are used as cover dressings for all phases of wound healing and are primary dressing for many types of post-operative wounds.
WO 03/088966 PCT/EP03/03618 Contact layers Contact layers are thin sheet dressings placed directly on an open wound to protect the wound tissue from direct contact with other agents or dressings applied to the wound. Secondary dressings are always used with contact layers.
Foam dressings Foam dressings are made primarily from polyurethane, but silicone is also used. They are available as either flat foam dressings or as fillers, and are intended for use on granulation and epithelializing wounds producing some exudate.
Gauze Woven gauze dressings are made from 100% cotton yarn. The threads are horizontally and vertically woven, with 10 to 20 separate manufacturing steps employed in the process of producing a 4 x 4 inch, 12-ply sponge. Woven gauze dressings come in a wide range of types and are commonly used for packing and debridement.
Nonwoven fabrics are neither woven nor knitted. The fibers are arranged such that they appear to be woven. Most nonwoven dressings are manufactured from a blend of rayon and polyester. Rayon provides softness and absorbency, while polyester provides strength. The primary application of nonwoven gauze dressings is for absorption and wrapping.
Impregnated gauze dressings Impregnated gauze dressings are woven or nonwoven materials in which substances have been incorporated into the dressing material.
Hydrocolloid dressings Hydrocolloid dressings are popular second-generation dressings, which are moderate absorptive, moisture-retentive, conformable to the wound, and self-adhesive. They are also occlusive, forming a barrier against bacterial contamination. In addition to being available in dimensional forms, hydrocolloids are supplied as powders, granules, pastes, and other specialised forms. The major functional components are gelatine, pectin, or related hydrocolloids. They are indicated for use on pressure ulcers, burns, and a variety of other wound types.
WO 03/088966 PCT/EP03/03618 9 Hydrogel dressings Hydrogels are semipermeable dressings of which water is the major component.
Glycerine or propylene glycol are included as humectants, and a co-polymer starch is sometimes added as absorptive. The dressings are available as gauze-impregnated wafers, sheets, and amorphous gels, and are indicated for partial- and full-thickness wounds nondraining to moderately draining.
Transparent film dressings Transparent film dressings are occlusive dressings consisting of a polyurethane membrane framed by an adhesive layer. The dressings vary in thickness, degree of occlusiveness, and other properties. Transparent film dressings are indicated for use on small surgical incisions, insertion points for peripheral and central venous catheters, superficial burns, partialthickness breakdown wounds, and as secondary dressings.
Biological and biosynthetic dressings This sector includes -a group of naturally absorptive and biological compatible collagen-based dressings -dressings constructed of related biocompatible amino acids and protein hydrolysates -dressings which combine synthetic and biologically derived materials The compounds of the formula I can be topically administered to human and other mammals such as dog, cat, horse, pig, cattle or sheep.
The pharmaceutical preparations normally contain from about 0.05 to about 5 preferably from 0.5 to 2 especially preferably by weight of the compounds of the formula I and/or their physiologically tolerable salts. Smaller and higher percentages are also possible.
In addition to the active ingredients of the formula I and/or their physiologically acceptable salts and to carrier substances, the pharmaceutical preparations can contain additives such as, for example, fillers, binders, lubricants, wetting agents, stabilizers, emulsifiers, preservatives, colorants, thickeners, diluents, buffer substances, solvents, solubilizers, agents for achieving a depot effect, salts for altering the osmotic pressure, coating agents or antioxidants. They can also contain two or more compounds of the formula I and/or their physiologically tolerable WO 03/088966 PCT/EP03/03618 salts. Furthermore, in addition to at least one compound of the formula I and/or its physiologically tolerable salts, the pharmaceutical preparations can also contain one or more other therapeutically or prophylactically active ingredients. Such additional active ingredients can be dexpanthenol, allantoin, dextranomer, and/or extracts of the Echinacea plant.
It is understood that changes that do not substantially affect the activity of the various embodiments of this invention are included within the invention disclosed herein. Thus, the following examples are intended to illustrate but not limit the present invention.
Example 1 Induction of VEGF gene expression by CPX Methods Cell culture The HRCH05 cells containing a stable transfected, HIF-1-dependent reporter gene were described previously (Wanner, R. et al. (2000) Epolones induce erythropoietin expression via hypoxia-inducible factor-la activation. Blood 96, 1558-1565). The human HepG2 hepatoma cell line was obtained from American Type Culture Collection (ATCC numbers HB-8065). All cell lines were cultured in Dulbecco's modified Eagle's medium (DMEM, high glucose, Life Technologies) supplemented with 10% heat-inactivated FCS, 100 U/ml penicillin, 100/ g/ml streptomycin, 1 x non-essential amino acids and 1 mM Na-pyruvate (all purchased from Life Technologies) in a humidified atmosphere containing 5% C02 at 37 0 C. Oxygen partial pressures in the incubator (Forma Scientific, model 3131) were either 140 mm Hg (20% Oz v/v, normoxia) or 7 mm Hg O2 v/v, hypoxia). Ciclopirox olamine (CPX), deferoxamine mesylate (DFX) and 2,2'-dipyridyl (DP) were purchased from Sigma. Stock solutions of CPX and DP were prepared in methanol at 0.5 M and 1 M, respectively. DFX was freshly dissolved at 10 mM into the cell culture medium.
Transient transfection, reporter gene and viability assays WO 03/088966 PCT/EP03/03618 11 HepG2 cells were transiently electroporated with a VEGF promoter-driven luciferase construct as described previously (Ikeda, et al. (1995) Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J. Biol. Chem.
270, 19761-19766). Following stimulation, transiently and stable transfected cells were lysed in passive lysis buffer (Promega) and the luciferase activity was determined using a luciferase assay kit according to the manufacturer's instructions (Promega) in a 96-well luminometer (MicroLumat LB96P, EG&G Berthold). Cell proliferation/viability was assessed by the 3-(4,5dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay as described (30, 31).
Absorbances at 570 nm were determined in a 96-well photometer (Rainbow, SLT Labsystems).
Results CPX in a concentration from 5pM to 20/pM concentrations strongly induced the HIF-1 a protein in normoxic HepG2 hepatoma cells after 6 and 24 hours of treatment. While no HIF-la protein could be detected in normoxic cells, hypoxia 02) also strongly induced HIF-la. The combination of CPX and hypoxia did not further increase HIF-la levels after 6 hours but rather decreased HIF-la levels after 24 hours of treatment.
As determined by Northern blotting of mRNA derived from HepG2 cells treated with CPX, DFX and DP for 24, 48 and 72 hours, these iron chelators also induced the expression of the endogenous HIF-1 target genes VEGF, glucose transporter-1 (Glut-1) and aldolase but not of the control genes L28 and p-actin.
The functionality of CPX-induced VEGF mRNA expression was further demonstrated by the accumulation of VEGF protein in the supernatant of the HepG2 cell culture, which increased in a dose-dependent manner following 6 or 24 hours of treatment.
A luciferase reporter gene driven by a 1180 bp VEGF promoter fragment was transiently transfected into HepG2 cells, which were split and treated with increasing concentrations of CPX for 24 hours. A dose-dependent increase in luciferase activity was observed, suggesting that CPX transcriptionally activates VEGF expression. In summary, these results demonstrate WO 03/088966 PCT/EP03/03618 12 that CPX can activate endogenous VEGF transcription, mRNA expression and secreted protein accumulation.
Example 2 Lack of HIF-1 target gene induction by CPX in the isolated perfused rat kidney Systemically administered DFX can induce ubiquitous HIF-1 stability and kidney-specific erythropoietin expression in mice (Wang, G. and Semenza, G. L. (1993) Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: implications for models of hypoxia signal transduction. Blood 82, 3610-3615). Regarding a topical application of CPX as a HIF-1-inducing agent for therapeutic angiogenesis, itwas important to test whether CPX could lead to a systemic induction of VEGF. As an ex vivo model, isolated rat kidneys were perfused for 3 hours under normoxic conditions with increasing concentrations of CPX. However, CPX did not induce the mRNA levels of the HIF-1 target genes VEGF, Glut-1 or aldolase at concentrations ranging from 0.1 pM to 100 pM. The higher CPX concentrations (33 pM and 100 pM) led to a down regulation of kidney function as indicated by a strong increase in the albumin and sodium excretion rates. Following perfusion with 3% oxygen for 3 hours, an increase in Glut-1 but not in VEGF and aldolase mRNA levels was observed which was not further elevated by CPX.
Example 3 Induction of angiogenesis in the chicken chorioallantoic membrane (CAM) by CPX Chick embryo chorioallantoic membrane (CAM) assay Method CAM assays were performed as described by Olivo, M. et al. (A comparative study on the effects of tumor necrosis factor-a (TNF-a), human angiogenic factor (h-AF) and basic fibroblast growth factor (bFGF) on the chorioallantoic membrane of the chick embryo, (1992). Anat. Rec. 234, 105-115). Briefly, fertilized eggs (purchased from Lohmann Tierzucht, Cuxhaven, Germany) were incubated at 37 °C in a humidified atmosphere. The eggs were kept on their sides and turned upside down twice a day. After 6 days, a small hole was drilled through the shell into the air sac (visualized using a strong light source) and a window of approximately 0.5 cm 2 was WO 03/088966 PCT/EP03/03618 13 sawed into the side of the egg. The window was sealed with tape and the eggs were reincubated until day 9, when 6-Cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone 2aminoethanol salt (CPX) was applied to the CAM using the Elvax" method (see Olivo, M. et al.
above). Therefore, ethylene/vinyl acetate copolymer beads (Elvax' 40L-03, DuPont, provided by C. H. Erbslih KG, Krefeld, Germany) were extensively washed in ethanol and dried under reduced pressure. The Elvax" beads were then dissolved in methylene chloride at 10% and CPX was added to the desired concentration. One drop (40/pL) of this solution was pipetted onto a siliconized glass slide and the solvent was allowed to evaporate completely. Using forceps, the Elvax' disc was carefully lifted from the glass slides and placed onto the CAM. At day 11, the window was enlarged and the CAM was documented using a digital camera (Olympus) coupled to an ocular of a stereomicroscope.
Result Based on the observations that CPX induced VEGF expression in cell culture (see example 1), the angiogenic capacity in an in vivo model of angiogenesis was analyzed. Therefore, the chicken CAM at day 9 of development was overlayed with inert polymer discs containing various concentrations of CPX or solvent only. After two days of incubation, no signs of angiogenesis could be observed with the solvent control discs. In contrast, polymer discs containing 50 mM CPX consistently induced CAM angiogenesis as evidenced by numerous newly formed, radially arranged vessels. A total of 10 CAMs treated with 50 mM CPX showed similar angiogenesis, while all 7 control CAMs lacked any signs of angiogenesis. 5 mM CPX was indistinguishable from the controls and 500 mM CPX was toxic to the chick embryo.
Example 4 Mouse skin wound model Method Both ears of adult NMRI mice were wounded under anesthesia with 100 mg/kg Ketamine (Narketan") and 5 mg/kg Xylazine (Rompun") by punch-through holes of 2 mm diameter using a standard ear-punching tool. The ears were treated daily with a common skin cream containing (Batrafen") or not containing 1% (wlv) CPX. One ear was treated with CPX and the Sother ear with the control cream. The amount of cream was sufficient to cover the C hole and was equally distributed over the entire ear.
Result
\O
CPX can induce angiogenesis in a mouse skin wound model Punch-through ear holes of 2 mm diameter (a widespread way of marking mice in 00 Sanimal facilities) were treated daily with a commercially available dermal cream C- containing 1% CPX on one ear and a CPX-free but otherwise identical common tc, dermal cream on the other ear, respectively. CPX can cause reddening of the c wound margin, which was never observed on the healthy skin area of the same ear. In this series 4 of 10 animals showed similar effects and none of the animals had more pronounced reddening on the placebo-treated wound margin than on the CPX-treated wound margin. The reddening induced by CPX might be enhanced vessel growth.
Comprises/comprising and grammatical variations thereof when used in this specification are to be taken to specify the presence of stated features, integers, steps or components or groups thereof, but do not preclude the presence or addition of one or more other features, integers, steps, components or groups thereof.
Claims (12)
- 2. The use as claimed in claim 1, wherein Ar in the compound of the formula I is a bicyclic system, which is derived from the group consisting of: biphenyl, diphenylalkane and diphenyl ether.
- 3. The use as claimed in claim 1, wherein the compound of formula I contains a cyclohexyl radical in the position R 4
- 4. The use as claimed in claim 1, wherein the compound of formula I contains an octyl radical of the formula -CH 2 -CH(CH 3 )-CH 2 -C(CH 3 3 in the position R 4 The use as claimed in claim 1, wherein the compound of formula I is 1- hydroxy-4-methyl-6-[4-(4-chlorophenoxy)phenoxymethyl]-2-(1 H)pyridone, 1- hydroxy-4-methyl-6-cyclohexyl-2-(1 H)pyridone or 1-hydroxy-4-methyl-6-(2,4,4- trimethylpentyl)-2-(1 H)pyridine.
- 6. The use as claimed in any one of claims 1 to 5, wherein any one or more of the compounds of formula I are administered alone or in mixtures thereof.
- 7. The use as claimed in any one of claims 1 to 5, wherein the dose of the C compound of formula I in the pharmaceutical preparation is from about 0.05% to o about by weight of the compound of the formula I and/or their physiologically tolerable salts. \O
- 8. The use as claimed in claim 7, wherein the dose of the compound of c formula I in the pharmaceutical compound is 0.05% to about 2% by weight. o00 (N N 9. The use as claimed in claim 7, wherein the dose of the compound of q formula I in the pharmaceutical compound is about 1% by weight. The use as claimed in claim 1, wherein the pharmaceutical preparation contains in addition an active ingredient.
- 11. The use as claimed in claim 10 wherein the active ingredient is selected from dexpanthenol, allantoin, dextranomer, extracts of the Echinacea plant and a mixture of said ingredients.
- 12. A method for wound healing in an animal, wherein the wounds are selected from the group consisting of: crush wounds, cuts, gunshot wounds, incisions, squeeze wounds, stab wounds and wounds due to surgery or plastic surgery, which method comprises administering topically to the animal in the form selected from the group consisting of: emulsions, ointments, solutions, tinctures, powders, aerosols, foams, cream and gels, 1-hydroxy-2-pyridones compounds of the formula 1 R2 R R 3 RR(I) 4 R N 0 OH in which R 1 R 2 and R 3 are identical or different and are a hydrogen atom or alkyl having 1-4 carbons atoms, and SR 4 is a saturated hydrocarbon radical having 6 to 9 carbon atoms or a radical of C the formula II C-I Y Z is a single bond or the divalent radical comprising: a) O, or c) -C(R 5 )(R 6 wherein R 5 and R 6 are identical or different and are or a moisture thereof, wherein if 2 or more wher and/or S atoms or a mixture thereof are present, each 0 or S atom is separated by at least X is S or O, 2 carbon a hydrogen atom or up 2 halogen atoms such as chlorine and/or bromine, Z is a single bond or the foregoing bivalent radicals, the free valences of the carbon atoms of a) O, or b) S, or c) wherein R 5 and R 6 are identical or different and are independ bivalent radical are saturated by a hydrogen atom or (C-C4)-alkyl or a mixture thereof; and Ar is an aromatic ring system having 2 to 10 carbon in the form of a chain,tuted which optionally further cals fromprises one group consisre of the followine, chlorine, bromine, i) a carbon-carbon double bond, or methoxy, (CC)aky, trifluor a moisturethyl and trifluoromethoxy f, wherein if 2 or mor in salt for S atoms or a mixture thereof are presentin claim 12, each or S atom is separated by at least 2 carbon atoms; and, in any of the foregoing bivalent radicals, the free valences of the carbon atoms of said bivalent radical are saturated by a hydrogen atom, (C1-C4)-alkyl, or a mixture thereof; and Ar is an aromatic ring system having up to two rings which can be substituted by up to three radicals from the group consisting of fluorine, chlorine, bromine, methoxy, (C1-C4)-alkyl, trifluoromethyl and trifluoromethoxy in free or in salt form.
- 13. The method as claimed in claim 12, wherein Ar in the compound of the formula I is a bicyclic system, which is derived from the group consisting of: biphenyl, diphenylalkane and diphenyl ether. O 14. The method as claimed in claim 12, wherein compound of formula I CN contains a cyclohexyl radical in the position R 4 The method as claimed in claim 12, wherein the compound of formula I Scontains an octyl radical of the formula -CH 2 -CH(CH 3 )-CH 2 -C(CH 3 3 in the position R 4 00 16. The method as claimed in claim 12, wherein the compound of formula I is 1- c hydroxy-4-methyl-6-[4-(4-chlorophenoxy)phenoxymethyl]-2-(1 H)pyridone, 1- rn hydroxy-4-methyl-6-cyclohexyl-2-(1 H)pyridone or 1-hydroxy-4-methyl-6-(2,4,4- O trimethylpentyl)-2-(1 H)pyridine.
- 17. The method as claimed in any one of 12 to 16, wherein any one or more of the compounds of formula I are administered alone or in mixtures thereof.
- 18. The method as claimed in any one of claims 12 to 16, wherein the dose of the compounds of formula I in the pharmaceutical preparation is from about 0.05% to about by weight of the compound of the formula I and/or their physiologically tolerable salts.
- 19. The method as claimed in any one of claims 12 to 18, wherein the compounds are administered in the form of a pharmaceutical compound together with an active ingredient. The method as claimed in claim 19 wherein the active ingredient is selected from dexpanthenol, allantoin, dextranomer, extracts of the Echinacea plant and a mixture of said ingredients. AVENTIS PHARMA DEUTSCHLAND GMBH WATERMARK PATENT TRADE MARK ATTORNEYS P24607AU00
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02008902A EP1354586A1 (en) | 2002-04-20 | 2002-04-20 | The use of hydroxpyridone-derivatives in wound healing |
EP02008902.5 | 2002-04-20 | ||
PCT/EP2003/003618 WO2003088966A1 (en) | 2002-04-20 | 2003-04-08 | The use of hydroxypyridone-derivatives in wound healing |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2003222802A1 AU2003222802A1 (en) | 2003-11-03 |
AU2003222802B2 true AU2003222802B2 (en) | 2008-01-03 |
Family
ID=28459510
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2003222802A Ceased AU2003222802B2 (en) | 2002-04-20 | 2003-04-08 | The use of hydroxypyridone-derivatives in wound healing |
Country Status (16)
Country | Link |
---|---|
US (1) | US20040014794A1 (en) |
EP (2) | EP1354586A1 (en) |
JP (1) | JP4709489B2 (en) |
AT (1) | ATE357915T1 (en) |
AU (1) | AU2003222802B2 (en) |
BR (1) | BR0309403A (en) |
CA (1) | CA2482972C (en) |
CY (1) | CY1106472T1 (en) |
DE (1) | DE60312840T2 (en) |
DK (1) | DK1499312T3 (en) |
ES (1) | ES2282615T3 (en) |
IL (1) | IL164536A (en) |
MX (1) | MXPA04009186A (en) |
PT (1) | PT1499312E (en) |
SI (1) | SI1499312T1 (en) |
WO (1) | WO2003088966A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009044403A2 (en) | 2007-10-05 | 2009-04-09 | Juvenis Ltd. | Injectable biodegradable polymer compositions for soft tissue repair and augmentation |
MX2012013879A (en) | 2010-06-01 | 2013-04-03 | Biotheryx Inc | Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases. |
GB201509847D0 (en) * | 2015-06-08 | 2015-07-22 | Nautilus Biosciences Canada Inc | Anti-dandruff agents |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0338173A1 (en) * | 1988-04-22 | 1989-10-25 | Ricoh Kyosan Inc. | Ionic dressing for topical administration of drugs to wounds and burns |
WO1999037300A1 (en) * | 1998-01-24 | 1999-07-29 | Aventis Pharma Deutschland Gmbh | Utilization of powder preparations containing hydroxypyridones for treating leg ulcers and decubitus ulcers |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5723119A (en) * | 1989-07-28 | 1998-03-03 | Schering Corporation | Method for enhancing wound healing/repair with IL-4 |
US5728546A (en) * | 1995-06-05 | 1998-03-17 | Human Genome Sciences, Inc. | Fibroblast growth factor 13 |
FR2737118B1 (en) * | 1995-07-28 | 1997-09-05 | Oreal | DERMATOLOGICAL OR PHARMACEUTICAL COMPOSITION, METHOD OF PREPARATION AND USE |
ATE239698T1 (en) * | 1995-10-25 | 2003-05-15 | Senju Pharma Co | ANGIOGENESIS INHIBITORS |
US5811078A (en) * | 1997-03-14 | 1998-09-22 | Adolor Corporation | Spray formulations of antihyperalgesic opiates and method of treating topical hyperalgesic conditions therewith |
US7387779B2 (en) * | 1998-06-17 | 2008-06-17 | Beth Israel Deaconess Medical Center | Anti-angiogenic proteins and fragments and methods of use thereof |
SE521431C2 (en) * | 1999-12-02 | 2003-11-04 | Sca Hygiene Prod Ab | Use of a pH buffering substance to prevent skin infections caused by Candida Albicans |
JP2005503120A (en) * | 2001-03-27 | 2005-02-03 | マサチューセッツ インスティテュート オブ テクノロジー | Methods and products for FGF dimerization |
EP1420786A2 (en) * | 2001-08-23 | 2004-05-26 | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | Methods of inhibiting formation of vascular channels and proliferation using pyridinone derivatives |
-
2002
- 2002-04-20 EP EP02008902A patent/EP1354586A1/en not_active Withdrawn
-
2003
- 2003-04-08 EP EP03718739A patent/EP1499312B1/en not_active Expired - Lifetime
- 2003-04-08 CA CA2482972A patent/CA2482972C/en not_active Expired - Fee Related
- 2003-04-08 DK DK03718739T patent/DK1499312T3/en active
- 2003-04-08 ES ES03718739T patent/ES2282615T3/en not_active Expired - Lifetime
- 2003-04-08 DE DE60312840T patent/DE60312840T2/en not_active Expired - Lifetime
- 2003-04-08 WO PCT/EP2003/003618 patent/WO2003088966A1/en active IP Right Grant
- 2003-04-08 SI SI200330773T patent/SI1499312T1/en unknown
- 2003-04-08 AU AU2003222802A patent/AU2003222802B2/en not_active Ceased
- 2003-04-08 JP JP2003585718A patent/JP4709489B2/en not_active Expired - Fee Related
- 2003-04-08 PT PT03718739T patent/PT1499312E/en unknown
- 2003-04-08 BR BR0309403-0A patent/BR0309403A/en not_active Application Discontinuation
- 2003-04-08 MX MXPA04009186A patent/MXPA04009186A/en active IP Right Grant
- 2003-04-08 AT AT03718739T patent/ATE357915T1/en active
- 2003-04-17 US US10/417,967 patent/US20040014794A1/en not_active Abandoned
-
2004
- 2004-10-12 IL IL164536A patent/IL164536A/en active IP Right Grant
-
2007
- 2007-05-21 CY CY20071100684T patent/CY1106472T1/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0338173A1 (en) * | 1988-04-22 | 1989-10-25 | Ricoh Kyosan Inc. | Ionic dressing for topical administration of drugs to wounds and burns |
WO1999037300A1 (en) * | 1998-01-24 | 1999-07-29 | Aventis Pharma Deutschland Gmbh | Utilization of powder preparations containing hydroxypyridones for treating leg ulcers and decubitus ulcers |
Also Published As
Publication number | Publication date |
---|---|
IL164536A (en) | 2011-11-30 |
WO2003088966A1 (en) | 2003-10-30 |
IL164536A0 (en) | 2005-12-18 |
CA2482972A1 (en) | 2003-10-30 |
US20040014794A1 (en) | 2004-01-22 |
JP2005529875A (en) | 2005-10-06 |
CA2482972C (en) | 2011-02-01 |
BR0309403A (en) | 2005-02-01 |
EP1499312B1 (en) | 2007-03-28 |
DK1499312T3 (en) | 2007-07-02 |
ATE357915T1 (en) | 2007-04-15 |
SI1499312T1 (en) | 2007-08-31 |
DE60312840D1 (en) | 2007-05-10 |
ES2282615T3 (en) | 2007-10-16 |
DE60312840T2 (en) | 2007-12-13 |
CY1106472T1 (en) | 2012-01-25 |
JP4709489B2 (en) | 2011-06-22 |
MXPA04009186A (en) | 2004-11-26 |
AU2003222802A1 (en) | 2003-11-03 |
EP1354586A1 (en) | 2003-10-22 |
PT1499312E (en) | 2007-05-31 |
EP1499312A1 (en) | 2005-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7054212B2 (en) | A novel fast-adhesive thin-film forming composition as an effective wound care procedure | |
US7576255B2 (en) | Silver-containing compositions, devices, and methods for making | |
KR100413202B1 (en) | Percutaneous Absorption | |
US20100215707A1 (en) | Activated creatinine and precursors thereof as antibacterial agents, compositions and products containing such agents and uses thereof | |
WO2001024839A9 (en) | Silver-containing compositions, devices and methods for making | |
AU2001264011B2 (en) | Use of biguanide derivatives for making a medicine having a wound healing effect | |
JPS62126119A (en) | Anti-inflammatory and analgesic application agent | |
JPH06104624B2 (en) | Transdermal agent | |
WO2008094002A1 (en) | Hydrogel formulations comprising active drugs for treating wounds | |
WO2009137074A1 (en) | Compositions and methods for treating diabetic ulcers | |
AU2003222802B2 (en) | The use of hydroxypyridone-derivatives in wound healing | |
WO2017025989A1 (en) | Method of wound healing | |
US20060165761A1 (en) | Wound dressings comprising vanadate complexed with organic ligands | |
AU2017281198A1 (en) | Wound healing using BRAF inhibitors | |
US20130243847A1 (en) | Activated creatinine and precursors thereof as antibacterial agents, compositions and products containing such agents and use thereof | |
RU2424813C2 (en) | Efficient hemostatic medication based on lithium and double lithium-zinc salt of polyacrylic acid | |
JP2004131495A (en) | Pharmaceutical composition for topical application containing nonsteroidal anti-inflammatory | |
US20130045269A1 (en) | Formulations and methods for wound treatment | |
JPH05271226A (en) | Wound curing promoter | |
TW200841880A (en) | A new type and highly efficient plaster of nitric oxide for burn & scald | |
Krivosheev | A Self-Adhesive Hemostatic Therapeutic System. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC1 | Assignment before grant (sect. 113) |
Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH Free format text: FORMER APPLICANT(S): AVENTIS PHARMA DEUTSCHLAND GMBH |
|
FGA | Letters patent sealed or granted (standard patent) | ||
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |